MedTrace Logo

A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

NCT07524348 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2026-05-11

No results posted yet for this study

Summary

This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

Conditions

Interventions

DRUG

E303

All participants will receive an intravenous (IV) infusion of E303

Sponsors & Collaborators

  • Samsung Bioepis Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-23
Primary Completion
2030-07-31
Completion
2030-07-31
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07524348 on ClinicalTrials.gov